Table 1 Baseline demographic and clinical characteristics of all included patients

Male, n (%)

21(39.6%)

12(37.5%)

0.846

Age (year)^a

55.26 ± 9.24

57.50 ± 7.37

0.248

Insulin therapy, n (%)

23(43.4%)

13(40.6%)

0.538

Oral hypoglycemic therapy, n (%)

30(56.6%)

19(59.4%)

0.538

Family history of DM, n (%)

29(54.7%)

15(46.9%)

0.483

Hemoglobin (g/dL)^a

12.98 ± 1.34

13.07 ± 1.05

0.764

Leukocytes (× 103/μL cells)^a

6.53 ± 1.67

6.53 ± 1.91

0.998

Platelets (× 103/μL cells)^a

223.57 ± 50.09

206.56 ± 53.82

0.144

Albumin (g/dL)^a

4.25 ± 0.42

4.30 ± 0.40

0.622

Bilirubin, total (mg/dL)^a

0.81 ± 0.15

0.78 ± 0.22

0.436

INR^a

1.29 ± 1.36

1.41 ± 1.75

0.722

AST (IU/L)^a

50.65 ± 24.36

51.59 ± 28.20

0.871

ALT (IU/L)^a

55.71 ± 27.48

64.13 ± 35.90

0.227

Creatinine (mg/dL)^a

1.02 ± 0.86

0.87 ± 0.15

0.304

AFP (ng/mL)^a

7.08 ± 5.01

7.41 ± 6.24

0.789

HCV RNA viral load (log10 IU/mL)^a

6.77 ± 6.661

6.77 ± 6.640

0.847

HbA1c (%)^a

8.17 ± 0.58

7.91 ± 0.69

0.062

FIB-4^b score^a

1.89 ± 0.85

1.75 ± 0.76

0.442